

## Commentary

### Integrating Metabolic and Surgical Care to Optimize Kidney Transplantation Outcomes in Patients with Obesity

Caroline C Jadlowiec<sup>1\*</sup>, Blanca C Lizaola-Mayo<sup>2</sup>, Kayla Mirie<sup>1</sup>, Charat Thongprayoon<sup>3</sup> and Wisit Cheungpasitporn<sup>3</sup>

<sup>1</sup>Division of Transplant Surgery, Mayo Clinic, Phoenix, AZ 85054, USA

<sup>2</sup>Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ 85054, USA

<sup>3</sup>Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55902, USA

#### Abstract

Recent studies have analysed the impact of obesity on kidney transplant outcomes, revealing worse one-year survival rates for patients with higher BMI levels. Data indicates that the prevalence of obesity among kidney transplant candidates is rising, with significant concerns about reduced transplant access and inferior outcomes. Integrated metabolic care, including surgical and medical treatments like sleeve gastrectomy and GLP-1 agonists, can improve kidney function and transplantation outcomes for patients with obesity and kidney disease. Data has also shown that BMI is insufficient to diagnose obesity and predict related cardio metabolic complications, thus additional diagnostic methods, such as waist circumference, should be considered. Robotic-assisted kidney transplantation has demonstrated excellent outcomes with minimal complications in patients with obesity. Multidisciplinary, integrated metabolic medicine programs in both the pre- and post-transplant phase of care are essential to optimize outcomes and address fragmented treatment pathways currently seen in healthcare institutions. Ongoing education for patients and medical care teams is essential to optimize metabolic care for kidney transplant recipients.

**\*Corresponding author:** Caroline C Jadlowiec, Division of Transplant Surgery, Mayo Clinic, 5777 East Mayo Boulevard, Phoenix, Arizona, 85054, USA, Tel+ 480-342-0437, E-mail: Jadlowiec.Caroline@Mayo.edu

**Citation:** Jadlowiec CC, Lizaola-Mayo BC, Mirie K, Thongprayoon C, Cheungpasitporn C (2025) Integrating Metabolic and Surgical Care to Optimize Kidney Transplantation Outcomes in Patients with Obesity. J Nephrol Renal Ther 11: 100.

**Received:** June 17, 2025; **Accepted:** June 26, 2025; **Published:** July 04, 2025

**Copyright:** © 2025 Jadlowiec CC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

#### Abbreviations

BMI: Body Mass Index

eGFR: Estimated Glomerular Filtration Rate

GLP-1: Glucagon-Like Peptide

ML: Machine Learning

RAKT: Robotic-Assisted Kidney Transplantation

SG: Sleeve Gastrectomy

UNOS: United Network for Organ Sharing database

### Integrating Metabolic and Surgical Care to Optimize Kidney Transplantation Outcomes in Patients with Obesity

In a recent publication, authors Thongprayoon et al., provide an analysis of the United Network for Organ Sharing database (UNOS)/OPTN database [1]. This study analysed kidney transplant recipients with a Body Mass Index (BMI)  $\geq 40$  kg/m<sup>2</sup> using unsupervised machine learning on data from 2010 to 2019. Five distinct clusters were identified based on recipient, donor, and transplant characteristics. Key findings by cluster are shown in (Table 1.) One-year patient survival rates ranged from 94.4% to 98.7%, with Cluster 2 performing the worst. One-year death-censored graft survival ranged from 93.0% to 98.8%, with Clusters 2 and 5 having the lowest rates. Based on this data, recipients with earlier access to transplant and living donation had better outcomes, and post-transplant support and socioeconomic factors likely influenced graft survival. Differences in outcomes can be further explained by differences in individual recipient characteristics. Importantly, this Machine Learning (ML)-based clustering approach offers a more nuanced and individualized risk assessment that goes beyond conventional BMI thresholds. By capturing the complex interplay among recipient comorbidities, donor characteristics, and transplant specific factors, these models enable clinicians to better predict both short- and long-term outcomes, refine candidate selection, and tailor perioperative and postoperative management strategies. Looking ahead, ML-driven phenotyping holds the potential to support truly personalized care pathways for transplant candidates with obesity shifting the field away from rigid BMI cut-offs and toward a more precise, patient centered approach to transplantation. Nonetheless, this study and the UNOS data are limited by the lack of detailed information on metabolic risk factors, like diabetes, hypertension, and hyperlipidaemia as well as interventions to optimize pre- or post-transplant outcomes.

The increasing prevalence of kidney disease can be significantly attributed to the currently rising rates of obesity. In 2023, the percentage of waitlisted candidates with elevated BMI levels saw a significant increase. Specifically, 19.3% had a BMI of 35 kg/m<sup>2</sup> or higher, while 27.5% had a BMI between 30 and 35 kg/m<sup>2</sup> [2]. Moreover, an increase in the number of individuals with obesity receiving kidney transplants is expected. This trend reflects the overall rise in obesity


Cluster	Key Cluster Characteristics
1	Predominantly white, non-sensitized, preemptive, or short dialysis duration, likely to have living donor transplants
2	Older, diabetic, over 3 years on dialysis, likely to receive standard KDPI deceased donor kidneys
3	Young, retransplants, sensitized
4	Diabetic, variable dialysis duration, received either non-ECD standard KDPI kidneys or living donor transplants
5	Young, retransplants, sensitized

**Table 1:** Key Cluster Characteristics Based on Recipient, Donor, and Transplant Variables. BMI, Body Mass Index; ECD, Extended Criterion Donor; KDPI, Kidney Donor Profile Index.

rates across the United States. Data has shown that obesity is linked to both reduced access to kidney transplant and concerns for inferior outcomes [3-5]. Segev et al. showed that the likelihood of kidney transplant decreased with increasing obesity, and the chances of being bypassed when an organ was available increased with higher BMI categories [3]. Similarly, a 2020 study found that BMI has a “J-Shaped” risk profile for overall graft loss, with higher risks for both low BMI and obesity although risk varied significantly with recipient characteristics such as age, diagnosis, gender, and race/ethnicity, suggesting that transplant considerations should be personalized rather than based on absolute BMI thresholds [4]. Presence of obesity in the transplant population presents distinct challenges that extend beyond those encountered in the general population [6]. Increased visceral adiposity adds surgical complexity, often resulting in longer operative times and elevating the risk of perioperative complications such as delayed wound healing and hernia formation [6]. In the postoperative period, excessive adiposity fosters a persistent pro-inflammatory state that contributes to graft inflammation, accelerates chronic allograft injury and undermines long-term graft survival [7]. Additionally, obesity heightens the risk of delayed graft function, driven by increased vulnerability to ischemia reperfusion injury and impaired microvascular perfusion. Furthermore, growing data suggests that BMI is a suboptimal tool to diagnose obesity and predict cardiometabolic complication from this disease [5]. Therefore, other diagnostic methods including waist circumference, dual x-ray composition and consideration of other comorbidities should be utilized in conjunction to BMI to better predict outcomes and complication risk. Not all individuals with elevated BMI carry the same metabolic risk. Some patients exhibit what is termed “metabolically healthy obesity,” characterized by preserved insulin sensitivity and minimal inflammation despite excessive body weight. In contrast, visceral adiposity is more closely linked to insulin resistance, systemic inflammation, and poor transplant outcomes. Evaluating fat distribution and metabolic function may offer more accurate assessment of transplant risk rather than relying on BMI alone [8].

As such, there has been increasing awareness surrounding the need for comprehensive metabolic care for patients with kidney disease and incorporation of this approach into both the pre- and post-transplant phases. Treatment modalities have included both surgical and medical treatment. In a study of 104 patients with obesity, those who underwent Sleeve Gastrectomy (SG) showed significant improvement in body mass index and were more likely to receive kidney transplants compared to nonsurgical controls [9]. Additionally, in a study assessing preemptive obese patients, the mean Estimated Glomerular Filtration Rate (eGFR) significantly increased on patients who underwent a pretransplant SG; those patients also saw a decrease in BMI and

insulin requirements. Accordingly, the use of pretransplant SG may improve kidney function and increase rates of preemptive kidney transplantation for candidates not yet on dialysis while also allowing for optimization of their metabolic profile [10]. Similarly, studies have found significant improvements in survival, urine albumin to creatinine ratio, and eGFR in kidney transplant recipients treated with Glucagon-Like Peptide-1 (GLP-1) agonists [11]. Beyond promoting weight loss, GLP-1 receptor agonists improve glycemic control, enhance insulin sensitivity and reduce systemic inflammation, all of which may help mitigate chronic allograft injury [12]. In addition, GLP-1 agonists have been shown to lower proteinuria and improve endothelial function, offering potential renal protective benefits that extend beyond weight reduction alone [13]. These multifaceted effects make GLP-1 agonist particularly appealing for managing kidney transplant recipients with obesity, who often present with complex and interrelated metabolic disturbances. Unfortunately, treatment pathways for obesity, diabetes, kidney disease, and transplantation are often siloed with limited comprehensive treatment strategies within healthcare institutions (Figure 1). This fragmented care is further complicated by insurers who cover the cost of the kidney transplant but do not necessarily guarantee coverage for obesity treatment. In response to these challenges, several centers have begun developing integrated metabolic transplant programs that bring together expertise from transplant surgery, bariatric surgery, endocrinology, nutrition, and nephrology. These multidisciplinary models are designed to optimize candidate selection, streamline pre- and post-transplant metabolic care and ultimately improve both graft function and patient outcomes in this complex and high-risk population [14].



**Figure 1:** Cardio metabolic Risks Influencing Kidney Transplant Outcomes.

Lastly, experience with Robotic-Assisted Kidney Transplantation (RAKT) has also further developed as an opportunity to improve surgical outcomes in obese kidney transplant recipients by limiting wound and hernia-related complications. In a series of 239 patients with obesity undergoing RAKT, Tzvetanov et al demonstrated 98% and 93% graft survival at 1 and 3 years [15]. Wound complications occurred in 3.8% of patients, and there was a low incidence of surgical site infections. The study concluded that RAKT is safe for obese patients, with excellent outcomes and comparable data to national statistics.

In summary, rising obesity rates in the US correlate with increased obesity among kidney transplant recipients, negatively impacting

both access to transplant and outcomes. Comprehensive metabolic care, including medications such as GLP-1 agonists and surgical interventions like sleeve gastrectomy and robotic-assisted kidney transplantation, have shown promise in improving kidney function, transplant rates, and surgical outcomes for patients with obesity. It is essential to provide ongoing education to both patients and medical care teams about the benefits of comprehensive metabolic care. Additionally, there is a need for more inclusive medical benefits to ensure cost coverage.

## References

- Thongprayoon C, Mao SA, Jadlowiec CC, Mao MA, Leeaphorn N, et al. (2022) Machine Learning Consensus Clustering of Morbidly Obese Kidney Transplant Recipients in the United States. *Journal of clinical medicine* 11: 3288.
- Lentine KL, Smith JM, Lyden GR, Miller JM, Booker SE, et al. (2025) OPTN/SRTR 2023 Annual Data Report: Kidney. *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 25: mS22-S137.
- Segev DL, Simpkins CE, Thompson RE, Locke JE, Warren DS, et al. (2008) Obesity impacts access to kidney transplantation. *Journal of the American Society of Nephrology: JASN* 19: 349-355.
- Schold JD, Augustine JJ, Huml AM, Fatica R, Nurko S, et al. (2021) Effects of body mass index on kidney transplant outcomes are significantly modified by patient characteristics. *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 21: 751-765.
- Janssen I, Katzmarzyk PT, Ross R (2004) Waist circumference and not body mass index explains obesity-related health risk. *The American journal of clinical nutrition* 79: 379-384.
- Dobrzycka M, Bzoma B, Bieniaszewski K, Dębska-Ślizień A, Kobiela J (2022) Pretransplant BMI Significantly Affects Perioperative Course and Graft Survival after Kidney Transplantation: A Retrospective Analysis. *Journal of clinical medicine* 11: 4393.
- Puttarajappa CM, Schinstock CA, Wu CM, Leca N, Kumar V, et al. (2021) KDOQI US Commentary on the 2020 KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. *American journal of kidney diseases: the official journal of the National Kidney Foundation* 77: 833-856.
- Blüher M (2020) Metabolically Healthy Obesity. *Endocrine reviews* 41.
- Kukla A, Sahi SS, Navratil P, Benzo RP, Smith BH, et al. (2024) Weight Loss Surgery Increases Kidney Transplant Rates in Patients With Renal Failure and Obesity. *Mayo Clinic proceedings* 99: 705-715.
- Navratil P, Sahi SS, Smith BH, Denic A, Issa NS, et al. (2025) Impact of Sleeve Gastrectomy on Kidney Function and Preemptive Transplant in Kidney Transplant Candidates with Obesity. *Mayo Clinic proceedings* 100: 942-953.
- Sahi SS, Garcia Valencia O, Na J, Lemke A, Duffy D, et al. (2025) Benefits of Glucagon-like Peptide-1 Receptor Agonists After Kidney Transplantation. *Endocr Pract* 31: 798-804.
- Ertuglu LA, Porrini E, Hornum M, Demiray A, Afsar B, et al. (2021) Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation. *Transpl Int* 34: 1341-1359.
- de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, et al. (2022) Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). *Diabetes care* 45: 3075-3090.
- Ghanem OM, Pita A, Nazzal M, Johnson S, Diwan T, et al. (2024) Obesity, organ failure, and transplantation: A review of the role of metabolic and bariatric surgery in transplant candidates and recipients. *Am J Transplant* 24: 1534-1546.
- Tzvetanov IG, Spaggiari M, Tulla KA, Di Bella C, Okoye O, et al. (2020) Robotic kidney transplantation in the obese patient: 10-year experience from a single center. *Am J Transplant* 20: 430-440.



Advances In Industrial Biotechnology | ISSN: 2639-5665

Advances In Microbiology Research | ISSN: 2689-694X

Archives Of Surgery And Surgical Education | ISSN: 2689-3126

Archives Of Urology

Archives Of Zoological Studies | ISSN: 2640-7779

Current Trends Medical And Biological Engineering

International Journal Of Case Reports And Therapeutic Studies | ISSN: 2689-310X

Journal Of Addiction & Addictive Disorders | ISSN: 2578-7276

Journal Of Agronomy & Agricultural Science | ISSN: 2689-8292

Journal Of AIDS Clinical Research & STDs | ISSN: 2572-7370

Journal Of Alcoholism Drug Abuse & Substance Dependence | ISSN: 2572-9594

Journal Of Allergy Disorders & Therapy | ISSN: 2470-749X

Journal Of Alternative Complementary & Integrative Medicine | ISSN: 2470-7562

Journal Of Alzheimers & Neurodegenerative Diseases | ISSN: 2572-9608

Journal Of Anesthesia & Clinical Care | ISSN: 2378-8879

Journal Of Angiology & Vascular Surgery | ISSN: 2572-7397

Journal Of Animal Research & Veterinary Science | ISSN: 2639-3751

Journal Of Aquaculture & Fisheries | ISSN: 2576-5523

Journal Of Atmospheric & Earth Sciences | ISSN: 2689-8780

Journal Of Biotech Research & Biochemistry

Journal Of Brain & Neuroscience Research

Journal Of Cancer Biology & Treatment | ISSN: 2470-7546

Journal Of Cardiology Study & Research | ISSN: 2640-768X

Journal Of Cell Biology & Cell Metabolism | ISSN: 2381-1943

Journal Of Clinical Dermatology & Therapy | ISSN: 2378-8771

Journal Of Clinical Immunology & Immunotherapy | ISSN: 2378-8844

Journal Of Clinical Studies & Medical Case Reports | ISSN: 2378-8801

Journal Of Community Medicine & Public Health Care | ISSN: 2381-1978

Journal Of Cytology & Tissue Biology | ISSN: 2378-9107

Journal Of Dairy Research & Technology | ISSN: 2688-9315

Journal Of Dentistry Oral Health & Cosmesis | ISSN: 2473-6783

Journal Of Diabetes & Metabolic Disorders | ISSN: 2381-201X

Journal Of Emergency Medicine Trauma & Surgical Care | ISSN: 2378-8798

Journal Of Environmental Science Current Research | ISSN: 2643-5020

Journal Of Food Science & Nutrition | ISSN: 2470-1076

Journal Of Forensic Legal & Investigative Sciences | ISSN: 2473-733X

Journal Of Gastroenterology & Hepatology Research | ISSN: 2574-2566

Journal Of Genetics & Genomic Sciences | ISSN: 2574-2485

Journal Of Gerontology & Geriatric Medicine | ISSN: 2381-8662

Journal Of Hematology Blood Transfusion & Disorders | ISSN: 2572-2999

Journal Of Hospice & Palliative Medical Care

Journal Of Human Endocrinology | ISSN: 2572-9640

Journal Of Infectious & Non Infectious Diseases | ISSN: 2381-8654

Journal Of Internal Medicine & Primary Healthcare | ISSN: 2574-2493

Journal Of Light & Laser Current Trends

Journal Of Medicine Study & Research | ISSN: 2639-5657

Journal Of Modern Chemical Sciences

Journal Of Nanotechnology Nanomedicine & Nanobiotechnology | ISSN: 2381-2044

Journal Of Neonatology & Clinical Pediatrics | ISSN: 2378-878X

Journal Of Nephrology & Renal Therapy | ISSN: 2473-7313

Journal Of Non Invasive Vascular Investigation | ISSN: 2572-7400

Journal Of Nuclear Medicine Radiology & Radiation Therapy | ISSN: 2572-7419

Journal Of Obesity & Weight Loss | ISSN: 2473-7372

Journal Of Ophthalmology & Clinical Research | ISSN: 2378-8887

Journal Of Orthopedic Research & Physiotherapy | ISSN: 2381-2052

Journal Of Otolaryngology Head & Neck Surgery | ISSN: 2573-010X

Journal Of Pathology Clinical & Medical Research

Journal Of Pharmacology Pharmaceutics & Pharmacovigilance | ISSN: 2639-5649

Journal Of Physical Medicine Rehabilitation & Disabilities | ISSN: 2381-8670

Journal Of Plant Science Current Research | ISSN: 2639-3743

Journal Of Practical & Professional Nursing | ISSN: 2639-5681

Journal Of Protein Research & Bioinformatics

Journal Of Psychiatry Depression & Anxiety | ISSN: 2573-0150

Journal Of Pulmonary Medicine & Respiratory Research | ISSN: 2573-0177

Journal Of Reproductive Medicine Gynaecology & Obstetrics | ISSN: 2574-2574

Journal Of Stem Cells Research Development & Therapy | ISSN: 2381-2060

Journal Of Surgery Current Trends & Innovations | ISSN: 2578-7284

Journal Of Toxicology Current Research | ISSN: 2639-3735

Journal Of Translational Science And Research

Journal Of Vaccines Research & Vaccination | ISSN: 2573-0193

Journal Of Virology & Antivirals

Sports Medicine And Injury Care Journal | ISSN: 2689-8829

Trends In Anatomy & Physiology | ISSN: 2640-7752

Submit Your Manuscript: <https://www.heraldopenaccess.us/submit-manuscript>

Herald Scholarly Open Access, 2561 Cornelia Rd, #205, Herndon, VA 20171, USA.

Tel: +1 202-499-9679; E-mail: [finalproof@heraldopenaccess.org](mailto:finalproof@heraldopenaccess.org)

<http://www.heraldopenaccess.us/>